查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1847799

按檢測方法、病原體類型、最終用戶和樣本類型分類的醫療保健相關感染疾病診斷市場—2025-2032年全球預測

Healthcare-associated Infectious Disease Diagnostics Market by Test Method, Pathogen Type, End User, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，醫療保健相關感染疾病診斷市場將成長至 84.7 億美元，複合年成長率為 8.60%。

主要市場統計數據
基準年 2024 43.7億美元
預計年份：2025年 47.6億美元
預測年份：2032年 84.7億美元
複合年成長率 (%) 8.60%

制定了一系列緊迫的臨床、營運和政策要務，以加速採用下一代診斷技術，從而減少醫療保健相關感染疾病，改善病患安全結果。

醫療相關感染疾病對臨床醫生、實驗室專業人員和醫療系統而言都是一項持續且不斷變化的挑戰。快速、準確的診斷對於及時進行患者管理、抗菌藥物管理和感染預防項目至關重要。隨著臨床路徑的日益整合和住院容量壓力的加劇，診斷效能和工作流程的兼容性在醫療服務中變得越來越關鍵。

這種應用從三個相互關聯的視角建構了診斷格局：臨床效用、操作可行性和政策契合度。臨床醫生需要可操作的結果來立即做出治療決策。實驗室管理者必須在保持嚴格品管的同時，平衡檢測量、週轉時間和成本。政策制定者和感染控制負責人需要數據來支持計畫干預措施，並確保其符合報銷和監管要求。

因此，診斷生態系統的評判標準不再僅限於分析靈敏度，而是要看其能否整合到電子健康記錄、支持抗菌藥物管理目標以及抵禦供應鏈中斷。這種整合為深入分析技術變革、監管發展、商業性應對措施和實用建議奠定了基礎，這些內容將在後續章節中展開。

檢驗正在重塑醫療保健環境中診斷工作流程、實驗室操作和感染預防策略的變革性技術、監管和行為轉變

診斷領域正經歷著深刻的變革，這主要由技術進步、監管環境變化以及不斷湧現的臨床需求所驅動。分子生物學技術正從專業的標準實驗室轉移到更貼近患者的診療環境，從而實現更早的病原體檢測和更快速的治療調整。同時，免疫測量平台也在不斷發展，變得更加自動化和互聯互通，從而減少人工操作，並在高效能環境下提高檢測結果的可重複性。

法律規範和品質預期正在不斷發展，更加重視臨床檢驗和實際應用效能，這影響供應商設計檢測方法的方式以及實驗室實施新檢測方法的方式。臨床醫生在抗菌素抗藥性和感染預防意識的提高推動了行為轉變，促使他們尋求能夠提供及時、可操作資訊的診斷方法，而不僅僅是孤立的分析結果。

在營運層面，自動化和數位化整合正在重塑實驗室工作流程，規範流程以提高可靠性，同時創造機會將熟練的員工重新部署到更高價值的任務中。總而言之，這些動態意味著，診斷的評估不僅要看其準確性，還要看其如何促進醫療服務、減少不合理使用抗生素以及增強系統韌性。

分析2025年美國關稅對供應鏈、定價、製造地選擇和臨床採購行為的多面向影響

關稅和貿易政策的變化會對診斷供應鏈產生連鎖反應，影響零件、耗材和組裝設備。 2025年，關稅制度的變化影響了試劑生產商和儀器組裝的採購決策，促使一些機構實現供應商多元化並重新評估庫存策略。對於實驗室管理人員和採購團隊而言，這些變化使得他們在維持持續檢測能力的同時，更加重視控制成本。

製造商採取了各種緩解策略，包括將某些生產步驟轉移到近岸地區、最佳化材料清單以減少暴露的組件以及與供應商談判長期合約以穩定投入價格，而臨床相關人員則強調了可行的替代方案和交叉檢驗的工作流程的重要性，以確保在首選檢測套組供應有限的情況下，臨床工作的連續性。

這種更廣泛的政策轉變有可能加速整個診斷生態系的結構性變革。為此，醫療系統和實驗室網路正日益將供應鏈風險評估納入技術採納決策，在採購合約中製定緊急應變計畫，並倡導貿易政策的明確性，以減少營運中的不確定性。

提供精確的細分洞察，將檢測技術、病原體特異性診斷、終端使用者能力和檢體類型與臨床效用和營運規劃連結。

對市場區隔進行詳細分析，有助於深入了解價值創造點和營運摩擦點。依檢測方法分類，市場可分為免疫檢測、微生物學和分子診斷。免疫檢測包括化學冷光免疫檢測、酵素連結免疫吸附試驗 (ELISA) 和側向流動檢測法，每種方法在通量、靈敏度和易用性方面各有重點。微生物學工作流程包括培養、顯微鏡檢查和藥敏試驗，其中培養可細分為需氧培養和厭氧培養，這會影響實驗室佈局和培養方案。分子診斷包括等溫擴增、聚合酶鍊式反應 (PCR) 和定序，每種方法對基礎設施、人員能力和數據解讀的要求各不相同。

根據病原體的類型，細菌、真菌、寄生蟲和病毒的診斷策略各不相同。細菌檢測通常針對艱難梭菌、大腸桿菌、綠膿桿菌和金黃色葡萄球菌，快速鑑定和藥敏試驗結果可直接影響抗生素治療。真菌困難梭狀芽孢桿菌主要針對曲霉菌、念珠菌和新型隱球菌，這些病原體的檢測通常需要專門的檢測方法和臨床相關性分析。寄生蟲檢測，例如瘧原蟲和弓形蟲的檢測，往往側重於特定的臨床情況；而病毒檢測，例如冠狀病毒、流感病毒、諾羅病毒和呼吸道融合細胞病毒的檢測，則涵蓋常規監測和急診決策。

最終用戶的特徵決定了技術的採納和實施管道。診斷實驗室優先考慮規模、認證和實驗室間可比性，包括獨立實驗室和參考實驗室。同時，醫院重視與臨床團隊的整合，並透過臨床病理和微生物實驗室實現快速的住院病患工作流程。診所、急診和長期照護機構等即時照護現場需要緊湊的平台、簡化的工作流程和快速的周轉時間，這些因素會影響檢測方法的選擇和驗證策略。

檢體類型——血液（血清和全血）、腦脊髓液、呼吸道檢體（支氣管肺泡灌洗液、鼻咽拭子和痰液）、尿液（導尿管尿和中段尿）以及傷口拭子（深層組織拭子和淺表拭子）——進一步決定了分析前管理、物流和分析靈敏度閾值。檢測方法、目標病原體、最終用戶和樣本類型之間的相互作用構成了一個多維決策矩陣，相關人員在確定投資優先順序、選擇平台和設計交付管道時必須權衡這一矩陣。

解讀美洲、歐洲、中東和非洲以及亞太地區的區域動態，以揭示能力優勢、招募模式和策略市場進入考量。

區域動態對診斷技術的普及、監管協調和供應鏈架構有顯著影響。在美洲，成熟的檢測基礎設施和完善的報銷管道催生了對快速、高通量解決方案以及床邊檢測的需求。該地區的相關人員通常優先考慮整合性、可擴展性和供應商支援的模式。相反，由於監管環境、資源限制和公共衛生優先事項的差異，歐洲和中東/非洲的普及模式有所不同。在許多市場，集中式參考偵測與快速照護現場部署並存，以滿足緊急需求。

亞太地區的能力差異顯著，既有高度發展的都市實驗室網路，也有難以取得複雜平台的地區。這種多樣性正在影響製造商的策略，使其圍繞模組化系統、語言適配的軟體以及本地夥伴關係關係展開，以確保系統的實施和可維護性。在整個亞太地區，採購行為、公共衛生需求和基礎設施投資都會影響診斷的優先順序，而互聯互通和資料互通性正日益被視為區域監測和臨床決策的關鍵推動因素。

因此，策略性進入和規模化決策必須使當地監管管道、物流限制和臨床實踐規範與目標診斷解決方案的技術特性相符。能夠根據當地實際情況調整產品供應的相關人員，將更有利於實現持續的臨床應用和系統性影響。

透過對主要企業概況和競爭動態的分析，揭示影響診斷生態系統的產品系列、夥伴關係策略、創新管道和商業化方法。

企業行動和競爭定位是決定醫療機構診斷能力未來發展方向的核心因素。領先的製造商正著力建構產品組合策略，力求在高性能實驗室系統、照護現場和床邊檢測平台之間取得平衡，從而兼顧集中式檢測的經濟效益和分散式臨床需求。策略夥伴關係與分銷協議拓展了業務覆蓋範圍，並提供了在地化的服務能力；而創新研發則體現了多重檢測能力、自動化和數位化連接等優先發展方向。

產品差異化日益不僅取決於偵測分析效能，還取決於端到端的價值提案，包括儀器執行時間、耗材物流、雲端資料解讀以及實驗室人員培訓計畫。那些投資於產生可靠的上市後證據並與醫療系統合作進行試點計畫的公司，將贏得臨床使用者和採購團隊的信任。此外，透過減少一次性塑膠的使用和最佳化試劑包裝來提升永續性的競爭優勢，也將影響採購偏好和長期合作關係的維護。

隨著商業性參與企業適應不斷變化的政策環境和供應鏈壓力，有關製造規模、平台模組化和服務生態系統的策略選擇將決定醫療保健系統部署和擴展診斷解決方案以改善感染控制的難易程度。

為產業領導者提供切實可行、影響深遠的建議，以最佳化診斷部署、增強供應彈性，並使臨床工作流程與感染控制要求保持一致。

針對產業領導者的實際建議應將策略洞察轉化為採購、實驗室營運和臨床管治等各環節的可操作步驟。首先，在評估新平台時，應優先考慮互通性和連接性，以確保結果能夠與電子健康記錄、決策支援工具和監測系統無縫整合。其次，應將供應鏈風險評估納入採購流程，評估替代試劑來源、前置作業時間差異以及供應商緊急時應對計畫，以避免在供應短缺期間出現服務中斷。

第三，我們正在統一聯網實驗室的驗證和確認通訊協定，以便在保持可比性和品質保證的同時，實現新檢測方法的快速規模化應用。第四，我們正在加大對人才隊伍建設的投入，確保實驗室人員接受分子和數位化工作流程的訓練。第五，我們對新診斷方法採取分階段引入的方式，包括臨床測試、多學科審查和回饋機制，以了解其實際表現和對工作流程的影響。

最後，為了降低醫療系統客戶的實施風險，應盡可能使商業協議與以結果為導向的指標保持一致，包括運作保證、配套服務以及共同創建上市後證據。這些措施結合起來可以加速負責任地部署診斷創新技術，從而大幅減少感染相關的危害。

我們描述了一種嚴謹的混合調查方法，該方法結合了主要相關人員訪談、實驗室工作流程觀察和二手證據的整合，以支持可靠的研究結果。

本分析採用混合研究途徑，整合一手和二手證據，以得出可操作的見解。主要定性資料透過對實驗室主任、感染疾病臨床醫生、採購負責人和監管專家進行結構化訪談收集，以了解實踐現狀、未滿足的需求和實施障礙。此外，還對不同環境下的實驗室工作流程進行了直接觀察，以了解分析前變異性、通量限制和整合挑戰。

我們從同行評審文獻、監管指導文件和製造商技術規格中收集了二次性證據，以檢驗檢測屬性並檢驗性能聲明。在條件允許的情況下，比較評估採用了已發布的分析績效指標和已記錄的案例研究，以便為培訓、維護和連接提供實際參考。

透過標準化的訪談指南、主題編碼的交叉檢驗以及對解釋性綜合中所用假設的透明記錄，確保了分析的嚴謹性。最終形成的方法論優先考慮操作相關性和臨床適用性，確保結論能夠為負責採購、實驗室操作和感染控制實踐的決策者提供切實可行的指導。

這份綜合報告提煉了關鍵見解，並將其轉化為連貫的策略要點，供醫療保健領導者、實驗室管理者和政策制定者採取果斷行動。

這篇總結性綜述將分析提煉為對醫療保健領導者、實驗室管理者和政策制定者俱有策略意義的要點。診斷只有在臨床決策窗口期內提供可操作的資訊，並且實驗室工作流程的設計能夠維持高品質、及時的產出時，才能發揮最大的作用。技術創新——特別是分子方法和自動化免疫檢測——為轉變診斷模式創造了機遇，但成功實施取決於互通性、人員準備和供應鏈的穩健性。

如果政策和採購機制能夠獎勵真實世界證據的生成、支持人才隊伍建設，並在合約中納入緊急應變計畫，就能加速研發進程。技術上更勝一籌但與當地工作流程、監管環境或樣本物流不符的解決方案，難以實現持續推廣應用。因此，採取將臨床需求、實驗室能力和商業模式結合的整體方法，對於在感染預防和患者療效方面取得可衡量的改進至關重要。

綜上所述，這些研究結果表明，綜合規劃、跨職能協作和適應性籌資策略對於將診斷創新轉化為臨床和營運影響至關重要。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在醫院環境中整合快速分子診斷檢測方法來識別多重抗藥性細菌
  • 實施人工智慧驅動演算法以早期檢測術後患者的手術部位感染
  • 在門診環境中推廣照護現場CRISPR 的即時檢測方法，以快速識別醫院獲得性病原體
  • 在加護病房採用多重PCR檢測板同時檢測細菌及病毒性醫療相關感染疾病
  • 整合即時抗菌藥物敏感性檢測平台，以最佳化加護治療中的抗菌藥物管理
  • 開發用於即時追蹤院內感染爆發的高通量全基因組定序工作流程
  • 引入遠距感染疾病諮詢服務，以減少偏遠地區醫療機構的診斷延誤。
  • 奈米技術增強型生物感測器在住院病患血液感染疾病連續監測的應用
  • 引進基於雲端基礎的監測平台，用於追蹤醫院內多重抗藥性細菌的傳播模式
  • 利用機器人技術加速自動化微生物實驗室病原體鑑定和報告的成本效益分析

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 醫療保健相關感染疾病市場：檢測方法

  • 免疫檢測
    • 化學冷光免疫檢測
    • ELISA
    • 橫向流動化驗
  • 微生物學
    • 文化
      • 需氧培養
      • 厭氧培養
    • 顯微鏡
    • 敏感性測試
  • 分子診斷
    • 等溫擴增
    • PCR
    • 順序

9. 按病原體類型分類的醫療保健相關感染疾病診斷市場

  • 細菌
    • 困難梭狀芽孢桿菌
    • 大腸桿菌
    • 銅綠假單胞菌
    • 金黃色葡萄球菌
  • 真菌
    • 麴菌
    • 念珠菌
    • 新型隱球菌
  • 寄生蟲
    • 瘧疾原蟲
    • 弓形蟲
  • 病毒性的
    • 新冠病毒
    • 流感病毒
    • 諾羅病毒
    • 呼吸道融合病毒（RSV）

第10章 按最終用戶分類的醫療保健相關感染疾病診斷市場

  • 診斷實驗室
    • 獨立實驗室
    • 參考實驗室
  • 醫院
    • 臨床病理實驗室
    • 微生物實驗室
  • 照護現場
    • 診所
    • 急診部
    • 長期照護機構

第11章 依樣本類型分類的醫療保健相關感染疾病診斷市場

  • 血
    • 血清
    • 全血
  • 腦脊髓液
  • 呼吸系統
    • 支氣管肺泡灌洗
    • 鼻咽拭子
    • 痰
  • 尿
    • 導尿管尿液
    • 中段尿
  • 傷口拭子
    • 深層組織樣本
    • 表面拭子

12. 各地區醫療保健相關感染疾病診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 醫療保健相關感染疾病診斷市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國醫療保健相關感染疾病診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Roche Diagnostics International AG
    • Abbott Laboratories
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • Becton, Dickinson and Company
    • bioMerieux SA
    • QIAGEN NV
    • Bio-Rad Laboratories, Inc.
    • DiaSorin SpA
Product Code: MRR-8760467AA424

The Healthcare-associated Infectious Disease Diagnostics Market is projected to grow by USD 8.47 billion at a CAGR of 8.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.37 billion
Estimated Year [2025] USD 4.76 billion
Forecast Year [2032] USD 8.47 billion
CAGR (%) 8.60%

Framing the urgent clinical, operational, and policy imperatives driving next-generation diagnostic adoption to curb healthcare-associated infections and improve patient safety outcomes

Healthcare-associated infectious diseases represent a persistent and evolving challenge for clinicians, laboratory professionals, and health systems alike. Rapid and accurate diagnostics are core to timely patient management, antimicrobial stewardship, and infection prevention programs. As clinical pathways become more integrated and pressure on inpatient capacity intensifies, diagnostic performance and workflow fit are increasingly decisive factors in care delivery.

This introduction frames the diagnostic landscape through three interlocking lenses: clinical utility, operational feasibility, and policy alignment. Clinicians require actionable results that inform immediate treatment decisions. Laboratory managers must balance throughput, turnaround time, and cost while maintaining rigorous quality controls. Policy makers and infection control leaders need data that supports programmatic interventions and aligns with reimbursement and regulatory imperatives.

Consequently, the diagnostics ecosystem is no longer judged by analytic sensitivity alone; it is evaluated by its ability to integrate into electronic medical records, to support antimicrobial stewardship objectives, and to withstand supply chain disruption. This synthesis sets the stage for deeper analysis of technological shifts, regulatory currents, commercial responses, and pragmatic recommendations that follow in subsequent sections.

Examining the transformative technological, regulatory, and behavioral shifts reshaping diagnostic workflows, laboratory practices, and infection prevention strategies across care settings

The diagnostic landscape is undergoing a profound transformation driven by converging technological advances, shifting regulatory expectations, and newly elevated clinical demands. Molecular methods have moved from specialized reference labs into near-patient settings, enabling earlier detection of pathogens and faster therapeutic alignment. At the same time, immunoassay platforms are evolving to offer greater automation and connectivity, reducing manual steps and enhancing reproducibility across high-throughput environments.

Regulatory frameworks and quality expectations have evolved to prioritize clinical validation and real-world performance, which influences how vendors design trials and how laboratories implement new assays. Behavioral shifts among clinicians-driven by heightened awareness of antimicrobial resistance and infection prevention targets-have increased demand for diagnostics that deliver timely, actionable intelligence rather than isolated analytic results.

Operationally, automation and digital integration are reshaping laboratory workflows, creating opportunities to reassign skilled staff to higher-value tasks while standardizing processes to improve reliability. These dynamics collectively point to a landscape in which diagnostics are evaluated not only on accuracy but on how they accelerate care, reduce inappropriate antimicrobial use, and enhance system resilience.

Analyzing the multifaceted implications of United States tariff actions in 2025 on supply chains, pricing dynamics, manufacturing location decisions, and clinical procurement behaviors

Tariff actions and trade policy changes have the potential to reverberate through diagnostic supply chains, affecting components, consumables, and assembled instruments. In 2025, shifts in tariff regimes influenced sourcing decisions for reagent manufacturers and instrument assemblers, prompting some organizations to reassess supplier diversification and inventory strategies. For laboratory managers and procurement teams, these developments brought renewed attention to cost containment while maintaining uninterrupted testing capacity.

Manufacturers responded through a range of mitigation strategies, including near-shoring certain production stages, optimizing bill-of-materials to reduce exposed components, and negotiating long-term supplier contracts to stabilize input pricing. Meanwhile, clinical stakeholders emphasized the importance of validated alternatives and cross-validated workflows to ensure clinical continuity when preferred test kits are constrained.

The broader implication is that policy shifts can accelerate structural change across the diagnostics ecosystem. In response, health systems and laboratory networks are increasingly incorporating supply-chain risk assessments into technology adoption decisions, embedding contingency plans into procurement contracts, and advocating for clarity in trade policy to reduce operational uncertainty.

Delivering incisive segmentation insights that connect test methodologies, pathogen-specific diagnostics, end user capacities, and sample type considerations to clinical utility and operational planning

A granular view of segmentation offers practical insight into where value is created and where operational friction can arise. By test method, the landscape divides among immunoassays, microbiology, and molecular diagnostics. Immunoassays encompass chemiluminescent immunoassays, ELISA, and lateral flow assays, each offering different balances of throughput, sensitivity, and ease of use. Microbiology workflows include culture, microscopy, and sensitivity testing, with culture further differentiated into aerobic and anaerobic techniques that influence laboratory layout and incubation protocols. Molecular diagnostics feature isothermal amplification, PCR, and sequencing approaches; each method carries distinct infrastructure, personnel competency, and data-interpretation requirements.

When considering pathogen type, diagnostic strategies differ for bacterial, fungal, parasitic, and viral agents. Bacterial testing frequently targets organisms such as Clostridium difficile, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus, where rapid identification and susceptibility insights directly affect antimicrobial therapy. Fungal diagnostics address Aspergillus species, Candida species, and Cryptococcus neoformans, which often require specialized assays and clinical correlation. Parasitic testing, including malaria parasites and Toxoplasma gondii, tends to be concentrated in specific clinical contexts, while viral testing for agents such as coronaviruses, influenza viruses, norovirus, and respiratory syncytial virus spans both routine surveillance and acute care decision-making.

End user characteristics shape adoption and implementation pathways. Diagnostic laboratories, including both independent and reference labs, prioritize scale, accreditation, and inter-laboratory comparability, whereas hospitals, through clinical pathology and microbiology laboratories, emphasize integration with clinical teams and rapid inpatient workflows. Point-of-care contexts such as clinics, emergency departments, and long-term care facilities demand compact platforms, simplified workflows, and rapid turnaround, which in turn influence assay format choices and validation strategies.

Sample type considerations-blood (serum and whole blood), cerebrospinal fluid, respiratory specimens (bronchoalveolar lavage, nasopharyngeal swabs, sputum), urine (catheterized and midstream), and wound swabs (deep tissue and surface swabs)-further dictate pre-analytical controls, transport logistics, and analytic sensitivity thresholds. The interplay among test method, pathogen target, end user, and sample type creates a multidimensional decision matrix that stakeholders must navigate when prioritizing investments, selecting platforms, and designing implementation pathways.

Interpreting regional dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific to reveal capacity strengths, adoption patterns, and strategic market entry considerations

Regional dynamics materially affect diagnostic adoption, regulatory alignment, and supply chain architecture. In the Americas, maturity in laboratory infrastructure and established reimbursement pathways create a demand environment for rapid, high-throughput solutions alongside near-patient testing; stakeholders here often prioritize integration, scalability, and vendor support models. Conversely, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory variation, resource constraints, and diverse public health priorities drive differential adoption patterns; in many markets, centralized reference testing coexists with pockets of rapid point-of-care rollouts in response to acute needs.

Asia-Pacific is characterized by a wide range of capabilities, from highly advanced metropolitan laboratory networks to regions with limited access to complex platforms. This diversity shapes manufacturer strategies around modular systems, language-appropriate software, and local partnerships to ensure adoption and serviceability. Across all regions, procurement behaviors, public health imperatives, and infrastructure investments influence how diagnostics are prioritized, with connectivity and data interoperability increasingly seen as cross-cutting enablers for regional surveillance and clinical decision-making.

Consequently, strategic entry and scale-up decisions must reconcile regional regulatory pathways, logistics constraints, and clinical practice norms with the technical attributes of targeted diagnostic solutions. Stakeholders that align product offerings with regional operational realities are better positioned to achieve sustained clinical uptake and system impact.

Profiling leading companies and competitive behaviors to highlight product portfolios, partnership strategies, innovation pipelines, and commercialization approaches that influence diagnostic ecosystems

Company behavior and competitive positioning are central determinants of how diagnostic capabilities evolve across care settings. Leading manufacturers emphasize a portfolio approach that balances high-throughput laboratory systems with point-of-care and near-patient platforms, thereby addressing both centralized testing economies and decentralized clinical demands. Strategic partnerships and distribution agreements expand geographic reach and provide local serviceability, while innovation pipelines reflect priorities such as multiplexing capability, automation, and digital connectivity.

Product differentiation increasingly hinges on end-to-end value propositions: not only the analytic performance of assays but also instrumentation uptime, consumable logistics, cloud-enabled data interpretation, and training programs for laboratory staff. Firms that invest in robust post-market evidence generation and that collaborate with health systems on implementation pilots secure credibility with clinical users and procurement teams. Additionally, a competitive emphasis on sustainability-through reduced single-use plastics and optimized reagent packaging-affects procurement preferences and long-term relationship management.

As commercial players adapt to evolving policy environments and supply-chain pressures, their strategic choices around manufacturing footprints, platform modularity, and service ecosystems will determine how readily health systems can deploy and scale diagnostic solutions in pursuit of improved infection management.

Presenting actionable, high-impact recommendations for industry leaders to optimize diagnostic deployment, strengthen supply resilience, and align clinical workflows with infection control imperatives

Actionable recommendations for industry leaders must translate strategic insight into implementable steps across procurement, laboratory operations, and clinical governance. First, prioritize interoperability and connectivity when evaluating new platforms so results can seamlessly integrate with electronic medical records, decision support tools, and surveillance systems; this reduces cognitive load on clinicians and supports stewardship programs. Second, embed supply-chain risk assessments into procurement cycles by evaluating alternate reagent sources, lead-time variability, and vendor contingency plans to avoid service disruptions during periods of constrained supply.

Third, standardize validation and verification protocols across networked laboratories to enable rapid scale-up of new assays while maintaining comparability and quality assurance. Fourth, invest in workforce development to ensure laboratory staff are trained in molecular and digital workflows; reallocating staff from repetitive tasks to higher-value data interpretation improves system resilience. Fifth, adopt a phased implementation approach for novel diagnostics that includes clinical pilots, multidisciplinary reviews, and feedback loops that capture real-world performance and workflow impact.

Finally, align commercial contracting with outcomes-oriented metrics where feasible, incorporating uptime guarantees, bundled service offerings, and joint post-market evidence generation to de-risk adoption for health system customers. Taken together, these steps will accelerate responsible deployment of diagnostic innovations that materially reduce infection-related harms.

Explaining a rigorous mixed-methods research methodology combining primary stakeholder interviews, laboratory workflow observations, and secondary evidence synthesis to underpin credible findings

This analysis is grounded in a mixed-methods research approach that synthesizes primary and secondary evidence to generate actionable insight. Primary qualitative data were gathered through structured interviews with laboratory directors, infectious disease clinicians, procurement officers, and regulatory experts to capture operational realities, unmet needs, and adoption barriers. These interviews were complemented by direct observations of laboratory workflows in diverse settings to understand pre-analytical variability, throughput constraints, and integration challenges.

Secondary evidence was curated from peer-reviewed literature, regulatory guidance documents, and manufacturer technical specifications to validate assay attributes and to triangulate performance claims. Where possible, comparative assessments leveraged published analytic performance metrics and documented implementation case studies to inform practical considerations around training, maintenance, and connectivity.

Analytic rigor was maintained through standardized interview guides, cross-validation of thematic coding, and transparent documentation of assumptions used in interpretive synthesis. The resulting methodology privileges operational relevance and clinical applicability, ensuring that conclusions are actionable for decision-makers responsible for procurement, laboratory operations, and infection control policy.

Concluding synthesis that distills key insights into coherent strategic takeaways aimed at healthcare leaders, laboratory managers, and policy makers for decisive action

This concluding synthesis distills the analysis into strategic takeaways for healthcare leaders, laboratory managers, and policy makers. Diagnostics are most impactful when they deliver actionable intelligence within clinical decision windows and when laboratory workflows are designed to sustain high-quality, timely outputs. Technological innovation-particularly in molecular methods and automated immunoassays-creates opportunities to shift diagnostic paradigms, but successful adoption depends on interoperability, workforce readiness, and supply-chain robustness.

Policy and procurement levers can accelerate deployment when they incentivize real-world evidence generation, support workforce development, and incorporate contingency planning into contracts. Regional dynamics and end-user characteristics matter: solutions that are technically excellent but misaligned with local workflow, regulatory realities, or sample logistics will struggle to achieve sustained uptake. Therefore, a holistic approach that aligns clinical needs, laboratory capabilities, and commercial models is essential for delivering measurable improvements in infection prevention and patient outcomes.

Taken together, the findings underscore that integrated planning, cross-functional collaboration, and adaptive procurement strategies are central to translating diagnostic innovation into clinical and operational impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of rapid molecular diagnostic assays for multidrug-resistant organism identification in hospital settings
  • 5.2. Implementation of AI-driven algorithms for early detection of surgical site infections in postoperative patients
  • 5.3. Expansion of point-of-care CRISPR-based assays for rapid identification of hospital-acquired pathogens in outpatient settings
  • 5.4. Adoption of multiplex PCR panels for simultaneous detection of bacterial and viral healthcare-associated infections in critical care units
  • 5.5. Integration of real-time antimicrobial susceptibility testing platforms to optimize antibiotic stewardship in intensive care
  • 5.6. Development of high-throughput whole genome sequencing workflows to track nosocomial infection outbreaks in real time
  • 5.7. Implementation of teleinfectious disease consultation services to reduce diagnosis delays in remote healthcare facilities
  • 5.8. Emergence of nanotechnology-enhanced biosensors for continuous monitoring of bloodstream infections in hospitalized patients
  • 5.9. Deployment of cloud-based surveillance dashboards for cross-hospital tracking of multidrug-resistant organism transmission patterns
  • 5.10. Cost-benefit analysis of automated microbiology laboratories leveraging robotics to accelerate pathogen identification and reporting

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Healthcare-associated Infectious Disease Diagnostics Market, by Test Method

  • 8.1. Immunoassays
    • 8.1.1. Chemiluminescent Immunoassay
    • 8.1.2. ELISA
    • 8.1.3. Lateral Flow Assays
  • 8.2. Microbiology
    • 8.2.1. Culture
      • 8.2.1.1. Aerobic Culture
      • 8.2.1.2. Anaerobic Culture
    • 8.2.2. Microscopy
    • 8.2.3. Sensitivity Testing
  • 8.3. Molecular Diagnostics
    • 8.3.1. Isothermal Amplification
    • 8.3.2. PCR
    • 8.3.3. Sequencing

9. Healthcare-associated Infectious Disease Diagnostics Market, by Pathogen Type

  • 9.1. Bacterial
    • 9.1.1. Clostridium Difficile
    • 9.1.2. Escherichia Coli
    • 9.1.3. Pseudomonas Aeruginosa
    • 9.1.4. Staphylococcus Aureus
  • 9.2. Fungal
    • 9.2.1. Aspergillus Species
    • 9.2.2. Candida Species
    • 9.2.3. Cryptococcus Neoformans
  • 9.3. Parasitic
    • 9.3.1. Malaria Parasites
    • 9.3.2. Toxoplasma Gondii
  • 9.4. Viral
    • 9.4.1. Coronavirus
    • 9.4.2. Influenza Virus
    • 9.4.3. Norovirus
    • 9.4.4. Respiratory Syncytial Virus

10. Healthcare-associated Infectious Disease Diagnostics Market, by End User

  • 10.1. Diagnostic Laboratories
    • 10.1.1. Independent Laboratories
    • 10.1.2. Reference Laboratories
  • 10.2. Hospitals
    • 10.2.1. Clinical Pathology Laboratories
    • 10.2.2. Microbiology Laboratories
  • 10.3. Point Of Care
    • 10.3.1. Clinics
    • 10.3.2. Emergency Departments
    • 10.3.3. Long Term Care Facilities

11. Healthcare-associated Infectious Disease Diagnostics Market, by Sample Type

  • 11.1. Blood
    • 11.1.1. Serum
    • 11.1.2. Whole Blood
  • 11.2. Cerebrospinal Fluid
  • 11.3. Respiratory
    • 11.3.1. Bronchoalveolar Lavage
    • 11.3.2. Nasopharyngeal Swabs
    • 11.3.3. Sputum
  • 11.4. Urine
    • 11.4.1. Catheterized Urine
    • 11.4.2. Midstream Urine
  • 11.5. Wound Swabs
    • 11.5.1. Deep Tissue Samples
    • 11.5.2. Surface Swabs

12. Healthcare-associated Infectious Disease Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Healthcare-associated Infectious Disease Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Healthcare-associated Infectious Disease Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Roche Diagnostics International AG
    • 15.3.2. Abbott Laboratories
    • 15.3.3. Danaher Corporation
    • 15.3.4. Thermo Fisher Scientific Inc.
    • 15.3.5. Siemens Healthineers AG
    • 15.3.6. Becton, Dickinson and Company
    • 15.3.7. bioMerieux SA
    • 15.3.8. QIAGEN N.V.
    • 15.3.9. Bio-Rad Laboratories, Inc.
    • 15.3.10. DiaSorin S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032